This article is more than 5 years old. Information may no longer be current.

Investigational SGLT2, ertugliflozin to begin phase 3 trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 3 trials of ertugliflozin, an investigational oral sodium glucose cotransporter inhibitor, are expected to begin later this year, according to a press release.

The manufacturer (Pfizer) announced they will collaborate with a subsidiary of Merck to develop and commercialize ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and sitagliptin (Januvia, Merck). The drug is indicated for the treatment of type 2 diabetes.